Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053662 · ClinicalTrials.gov registry record
Biomarker Identification for Bladder Cancer Patients
A clinical trial, sponsored by Ohio State University Comprehensive Cancer Center.
- Terminated
- Registry status
- 179
- Enrollment target
NCT02053662: Clinical Trial study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT02053662 is a clinical trial that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 179 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02053662 was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.
- TERMINATED
- Registry status
- 179 participants
- Enrollment target
Study Summary
To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them closely during and after treatment. This will include looking for changes in proteins and genes that might play a role in bladder cancer biology. The investigators will then compare the information obtained from the studies of blood, urine and cancer tissue between patients that are cured and those whose cancer comes back. The knowledge about these differences between patients can then potentially be used to develop a blood or urine test to tell us who has a high risk for having bladder cancer come back.
Primary Outcome
Predict and detect bladder cancer recurrence, specifically through development of biomarkers using bladder cancer tissue samples as well as blood and urine samples. Detect the recurrence of disease through development of blood and urine biomarkers using pre-therapy and post-therapy biospecimens.
Interventions
- PROCEDURE Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2014-01-21 |
| Est. Completion | 2023-11-16 |
Why NCT02053662 stopped before completion
NCT02053662 is an observational study that tracks outcomes without assigning an intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Sample Collection is the first listed.
NCT02053662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02053662 about?
NCT02053662 is a clinical study titled "Biomarker Identification for Bladder Cancer Patients". To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them close...
What is the current status of trial NCT02053662?
This trial is currently terminated. The enrollment target is 179 participants. The study started on 2014-01-21. Estimated completion is 2023-11-16.
What interventions are being tested in trial NCT02053662?
The interventions under investigation include: Sample Collection (PROCEDURE).
Who is sponsoring clinical trial NCT02053662?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI